INAB
IN8bio, Inc. - Common Stock (INAB)
$21
About IN8bio, Inc. - Common Stock (INAB)
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company was founded by Lawrence S. Lamb and William T. Ho on February 8, 2016 and is headquartered in New York, NY.
Details
Daily high
$1.48
Daily low
$1.17
Price at open
$1.46
52 Week High
$12.53
52 Week Low
$1.17
Market cap
5.6M
Dividend yield
0.00%
Volume
10.8M
Avg. volume
618,941
P/E ratio
-.18
IN8bio, Inc. - Common Stock News
Details
Daily high
$1.48
Daily low
$1.17
Price at open
$1.46
52 Week High
$12.53
52 Week Low
$1.17
Market cap
5.6M
Dividend yield
0.00%
Volume
10.8M
Avg. volume
618,941
P/E ratio
-.18